Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the
development and progression of Philadelphia chromosome–positive (Ph+) chronic …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more
potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL …

Beginning with imatinib a decade ago, therapy based on targeted inhibition of the BCR-ABL
kinase has greatly improved the prognosis for chronic myeloid leukemia (CML) patients. The …

Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that
accounts for about 15% of all cases of leukemia. This disorder results from the formation of …

Purpose The association between initial molecular response and longer-term outcomes with
nilotinib was examined. Patients and Methods Patients with imatinib-resistant or-intolerant …

Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that
specifically inhibits the BCR–ABL tyrosine kinase activity in patients with Philadelphia …

Purpose of review In this review, we emphasize up-to-date practical cytogenetic and
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …

Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of
chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are …